AN OPEN LABEL PHASE II PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENT OF TREATMENT WITH CPX-351 (CYTARABINE: DAUNORUBICIN) LIPOSOME FOR INJECTION IN ACUTE LEUKEMIAS AND MDS PATIENTS WITH MODERATE HEPATIC IMPAIRMENT

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celator

Protocol Number
CLTR0314-208

To Learn More Call
201-510-0910